Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Insomnia Market, by Distribution Channel
1.4.2 Asia Pacific Insomnia Market, by Therapy Type
1.4.3 Asia Pacific Insomnia Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Insomnia Market
Chapter 4. Asia Pacific Insomnia Market by Distribution Channel
4.1 Asia Pacific Hospital Market by Country
4.2 Asia Pacific Retail Market by Country
4.3 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Insomnia Market by Therapy Type
5.1 Asia Pacific Pharmacological Market by Country
5.2 Asia Pacific Non-Pharmacological Market by Country
Chapter 6. Asia Pacific Insomnia Market by Country
6.1 China Insomnia Market
6.1.1 China Insomnia Market by Distribution Channel
6.1.2 China Insomnia Market by Therapy Type
6.2 Japan Insomnia Market
6.2.1 Japan Insomnia Market by Distribution Channel
6.2.2 Japan Insomnia Market by Therapy Type
6.3 India Insomnia Market
6.3.1 India Insomnia Market by Distribution Channel
6.3.2 India Insomnia Market by Therapy Type
6.4 South Korea Insomnia Market
6.4.1 South Korea Insomnia Market by Distribution Channel
6.4.2 South Korea Insomnia Market by Therapy Type
6.5 Singapore Insomnia Market
6.5.1 Singapore Insomnia Market by Distribution Channel
6.5.2 Singapore Insomnia Market by Therapy Type
6.6 Malaysia Insomnia Market
6.6.1 Malaysia Insomnia Market by Distribution Channel
6.6.2 Malaysia Insomnia Market by Therapy Type
6.7 Rest of Asia Pacific Insomnia Market
6.7.1 Rest of Asia Pacific Insomnia Market by Distribution Channel
6.7.2 Rest of Asia Pacific Insomnia Market by Therapy Type
Chapter 7. Company Profiles
7.1 Eisai Co., Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Product Launches and Product Expansions:
7.1.5.2 Approvals and Trails:
7.2 Takeda Pharmaceutical Company Limited
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Approvals and Trails:
7.3 Vanda Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.3.4 Recent strategies and developments:
7.3.4.1 Approval and Trails:
7.4 Cadila Healthcare Ltd. (Zydus Cadila)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Sanofi S.A.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Geographical Expansions:
7.6 Merck Group
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Acquisition and Mergers:
7.9.2.2 Geographical Expansions:
7.10. Purdue Pharma L.P.
7.10.1 Company Overview
Unique Offerings 
